Johnson and Johnson

COVID-19 Vaccine Tolerance in Patients with Rheumatoid Arthritis

Researchers created an online questionnaire for RA and AIRD patients to self-report short-term COVID-19 vaccine-related adverse events. Vaccines included in the study were Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Covaxin, and Sinopharm. The most common coexisting autoimmune diseases were thyroid disorders, systemic lupus erythematosus (SLE) and Sjogren’s syndrome (10.0%, 2.6%, and 2.5%, respectively).

Read More »

Vaccine Efficacy in SLE Patients Across Multiple Variants

A new study investigated vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, in SLE patients. This is one of the first studies on vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, especially in an autoimmune disease patient cohort.

Read More »

COVID-19 Vaccine Outcomes in Dermatomyositis Patients

A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.

Read More »